Clinical Trial Update: Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with low-dose cyclophosphamide in patients with recurrent ovarian epithelial cancer or primary peritoneal cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-05-12